Skip to main content
Clinical Trials/IRCT20210724051972N1
IRCT20210724051972N1
Completed
Phase 2

Investigation of the effectiveness of anti-anxiety medication (Buspirone and Mirtazapine) on anxiety and gastrointestinal symptoms of functional dyspepsia patients with postprandial discomfort syndrome

Birjand University of Medical Sciences0 sites120 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Functional dyspepsia.
Sponsor
Birjand University of Medical Sciences
Enrollment
120
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Willingness to participate in the study after explaining all the objectives of the research and the advantages and disadvantages of the methods
  • Failure to receive psychological treatment before entering the study
  • Lack of other structural or functional gastrointestinal disorders
  • No other organic disease
  • Possibility to keep the type and amount of drug used during the research period if the drug is used
  • No alcohol and drugs
  • No psychotic disorder and personality disorder
  • Absence of alarm signs such as gastrointestinal bleeding, blood in the stool, fever, weight loss, anemia, nocturnal diarrhea, severe heartburn
  • Age between 18 and 50 years

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials